Estimating elasticities from linear regressions

This post aims to show how elasticities can be estimated directly from linear regressions.
Elasticity measures the association between two numeric variables expressed in percentages, whose interpretation is the percentage increase in one variable associated with a 1% change in another one. Elasticities have served economics for a long time, basically because they allow comparison between very different settings when changes in levels (e.g. dollars) are difficult to interpret. Take for instance a company that produces both cars and chocolate bars. If they want to know how changes in the price of both products would impact their demand, in order to determine which price to increase and which to maintain, the comparison would be a mess. A $100 change would mean nothing for the demand of cars but would destroy demand for chocolates. Similarly, a decrease in 100K people in the chocolate bars’ demand is probably just a dent, but the same amount could represent a significant portion of the car’s market. Changes in percentages are a way to standardize change and its consequences. In health economics, elasticities are becoming more common because they are able to show fair comparisons between variables with heterogenous behavior depending on the context.

The most common elasticities are price and income. The income elasticity of any variable would be the percentage change in that variable associated with a 1% change in income; the elasticity price would be the percentage change in a variable associated with a 1% change in its own price. In economics, that variable usually would be the demand of a given good. In health economics, that variable could be any number of things.

For example, let’s say we want to estimate the income elasticity of BMI. The elasticity would be expressed as:

\displaystyle \epsilon_I = \dfrac{\Delta \% BMI}{\Delta \% Income} = \dfrac{\Delta BMI}{\Delta Income}* \dfrac{Income}{BMI}

where ∆ stands for variation and shows the variation of BMI or Income from one point to another in their joint distribution. In order to make this change infinitesimal, and therefore estimate the elasticity in the whole distribution, we can express those changes with differentials: ε_I = dQ/dP*Income/BMI

Now, to obtain elasticities directly from linear regressions we should use the logarithmic forms of the variables:

\displaystyle ln(BMI) = \beta_0 + \beta_1 * ln(Income) = f(Income)

The BMI is a function of income. The function can be expressed as:

\displaystyle f(Income) = BMI = e^{ \beta_0 + \beta_1 * ln(Income)}

To find the change in BMI associated with a change in income we should derive this function by Income. Given the form of the function we use the chain rule:

\displaystyle f(x)=g(h(x)) ; f'(x)=g'(h(x))*h'(x)

Where: \displaystyle  g(h) = e^h , h(Income) = \beta_0 + \beta_1 *ln(Income)

\displaystyle g'(h)= e^h ,h'(Income) = \beta_1 * \dfrac{1}{Income}

Then:

\displaystyle f'(Income) = e^{ \beta_0 + \beta_1 * ln(Income)} * \beta_1 * \dfrac{1}{Income}

\displaystyle \dfrac{\partial BMI}{\partial Income} = e^{ln(BMI)} * \beta_1 * \dfrac{1}{Income} = BMI * \beta_1 * \dfrac{1}{Income}

\displaystyle \beta_1 = \dfrac{ \partial BMI}{ \partial Income} * \dfrac{Income}{BMI}

Thus, the β_1 coefficient is the estimation of the income elasticity. The same procedure could be applied to find the price elasticity. It’s interesting to notice that if only the independent variable were in its logarithmic form, the derivation would be easier, and the coefficient would be:

\beta_1 = \dfrac{ \partial BMI}{ \partial Income} * \dfrac{Income}{1}

Then, to estimate the elasticity it would be necessary to divide the coefficient by a measure of BMI, probably the mean to account for the whole distribution, as Sisira et al. did in their paper. However, in this case would be necessary to carefully select a good average measure. This method would be useful if we prefer to interpret other covariates’ coefficients using BMI rather than ln⁡(BMI).

Commonly Misunderstood Concepts in Pharmacoepidemiology

By Erik J. Landaas, MPH, PhD Student and Naomi Schwartz, MPH, PhD Student

 

Epidemiologic methods are central to the academic and research endeavors at the CHOICE institute. The field of epidemiology fosters the critical thinking required for high quality medical research. Pharmacoepidemiology is a sub-field of epidemiology and has been around since the 1970’s. One of the driving forces behind the establishment of pharmacoepidemiology was the Thalidomide disaster. In response to this tragedy, laws were enacted that gave the FDA authority to evaluate the efficacy of drugs. In addition, drug manufacturers were required to conduct clinical trials to provide evidence of a drug’s efficacy. This spawned a new and important body of work surrounding drug safety, efficacy, and post-marketing surveillance.[i]

In this article, we break down three of the more complex and often misunderstood concepts in pharmacoepidemiology: immortal time bias, protopathic bias, and drug exposure definition and measurement.

 

Immortal Time Bias

In pharmacoepidemiology studies, immortal time bias typically arises when the determination of an individual’s treatment status involves a delay or waiting period during which follow-up time is accrued. Immortal time bias is a period of follow-up during which, by design, the outcome of interest cannot occur. For example, the finding that Oscar winners live longer than non-winnersis a result of immortal time bias. In order for an individual to win an Oscar, he/she must live long enough to receive the award.  A pharmacoepidemiology example of this is depicted in Figure 1. A patient who receives a prescription may survive longer because he/she must live long enough to receive a prescription while a patient who does not receive a prescription has no survival requirements.  The most common way to avoid immortal time bias is to use a time-varying exposure variable. This allows subjects to contribute to both unexposed (during waiting period) and exposed person time.

 

Figure 1. Immortal Time Bias

Picture2_pharmepi post.png 

Lévesque, Linda E., et al. “Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.” Bmj 340 (2010): b5087.

Protopathic Bias or Reverse Causation

Protopathic bias occurs when a drug of interest is initiated to treat symptoms of the disease under study before it is diagnosed. For example, early symptoms of inflammatory bowel disease (IBD) are often consistent with the indications for prescribing proton pump inhibitors (PPIs). Thus, many individuals who develop IBD have a history of PPI use. A study to investigate the association between PPIs and subsequent IBD would likely conclude that taking PPIs causes IBD when, in fact, the IBD was present (but undiagnosed) before the PPIs were prescribed.  This scenario is illustrated by the following steps:

  • Patient has early symptoms of an underlying disease (e.g. acid reflux)
  • Patient goes to his/her doctor and gets a drug to address symptoms (e.g. PPI)
  • Patient goes on to develop a diagnosis of having IBD (months or even years later)

It is easy to conclude from the above scenario that PPIs cause IBD, however the acid reflux was actually a manifestation of underlying IBD that was not yet diagnosed.  Protopathic bias occurs in this case because of the lag time between first symptoms and diagnosis. One effective way to address protopathic bias is by excluding exposures during the prodromal period of the disease of interest.

 

Drug Exposure Definition and Measurement 

Defining and classifying exposure to a drug is critical to the validity of pharmacoepidemiology studies. Most pharmacoepidemiology studies use proxies for drug exposure, because it is often impractical or impossible to measure directly (e.g. observing a patient take a drug, monitoring blood levels). In lieu of actual exposure data, exposure ascertainment is typically based on medication dispensing records. These records can be ascertained from electronic health records, pharmacies, pharmacy benefit managers (PBMs), and other available healthcare data repositories. Some of the most comprehensive drug exposure data are available among Northern European countries and large integrated health systems such as Kaiser Permanente in the United States. Some strengths of using dispensing records to gather exposure data are:

  • Easy to ascertain and relatively inexpensive
  • No primary data collection
  • Often available for large sample sizes
  • Can be population based
  • No recall or interviewer bias
  • Linkable to other types of data such as diagnostic codes and labs

Limitations of dispensing records as a data source include:

  • Completeness can be an issue
  • Usually does not capture over-the-counter (OTC) drugs
  • Dispensing does not guarantee ingestion
  • Often lacks indication for use
  • Must make some assumptions to calculate dose and duration of use

Some studies collect drug exposure data using self-report methods (e.g. interviews or surveys). These methods are useful when the drug of interest is OTC and thus not captured by dispensing records. However, self-reported data is subject to recall bias and requires additional considerations when interpreting results. Alternatively, some large epidemiologic studies require patients to bring in all their medications when they do their study interviews (eg. bring your brown bag of medications). This can provide a more reliable method of collecting medication information than self-report.

It is also important to consider the risk of misclassification of exposure. When interpreting results, remember that differential misclassification (different for those with and without disease) can result in either an inflated measure of association, or a measure of association that is closer to the null. In contrast, non-differential misclassification (unrelated to the occurrence or presence of disease) shifts the measure of association closer to the null. For further guidance on defining drug exposure, please look at Figure 2.

 

Figure 2. Checklist: Key considerations for defining drug exposure

Picture3_pharmepi post.png
Velentgas, Priscilla, et al., eds. Developing a protocol for observational comparative effectiveness research: a user’s guide. Government Printing Office, 2013.

As alluded to above, pharmacoepidemiology is a field with complex research methods. We hope this article clarifies these three challenging concepts.

 

 

[i](Pinar Balcik, Gulcan Kahraman “Pharmacoepidemiology.” IOSR Journal of Pharmacy (e)-ISSN: 2250-3013, (p)-ISSN: 2319-4219 Volume 6, Issue 2 (February 2016), PP. 57-62)

Vaccine education in Africa: unmet needs and current programs

Written by Karen Guo.

Disease burden:

Childhood immunization – inducing immunity by applying a vaccine – almost guarantees protection from many major diseases. Childhood vaccination prevents 2 million deaths per year worldwide and is widely consideredto be overwhelmingly good by the scientific community.   However, 2.5 million deaths a year continue to be caused by vaccine-preventable diseases, mainly in Africa and Asia among children less than 5 years old.

Demand-related factors, such as parents’ knowledge about vaccination and immunization and their attitudes towards them, are also likely to influence uptake. What remains unclear, however, is whether people’s attitudes are more strongly influenced by the perceived benefits of vaccination or by the perceived risks of not being vaccinated.

AVW3

Education unmet needs:

Parents’ knowledge about vaccinations is poor, and the knowledge they do have is often wrong. It appears that there is no association between parents’ knowledge and vaccination coverage rates, and the public seems to accept vaccinationdespite limited knowledge about it. One thing is clear, however: when parents resist vaccination, it is because they want to protect their children from harm. In 2003, political and religious leaders in three Nigerian states boycotted a WHO polio vaccination campaign, claiming that the vaccine caused sterility and AIDS. Similarly, certain Hindu and Muslim groups in India have long held the belief that vaccination is a covert method of family planning, primarily targeting Muslims. The greater acceptance of vaccination found among Javanese migrants as opposed to Acehnese villagersin the same area has been attributed to the former’s more positive cultural attitudes towards health. Both groups were found to have an equally poor understanding of vaccination and health in general. Similarly, followers of the Aga Khan in Pakistan were found to be receptive to ‘biomedical’ or ‘western’ medicine and reasoning despite the fact that as a group they were largely illiterate and understood little about vaccination. Cultural receptivity to perceived modernity and education, as well as trust in health workers, were considered to be the most important factors influencing attitudes. In short, knowing little about vaccination does not necessarily translate into negative attitudes towards it; factors such as trust (e.g. in health-care providers or ‘western’ medicine) and culture may be more influential. The impact of high levels of knowledge on subsequent attitudes towards vaccination is unknown.

The fundamental question is whether or not resources should be invested in improving parents’ knowledge of and attitudes towards vaccination. Although the evidence is unclear, it is commonly believed that strengthening advocacy, communication and social mobilization will enhance informed and willing participation in vaccination programs and that vaccination strategies are likely to be more successful if they are based on an understandingof sociocultural behavior.  Yet these approaches are not routinely incorporated into vaccination policy. Since factors influencing demand vary greatly by region and context, findings from one population cannot always be extrapolated to another. Thus, simple operational research into local knowledge and attitudes should become an essential part of every vaccination campaign. Current research into parents’ knowledge and attitudes towards childhood vaccination is disproportionately low considering the enormous scale and relevance of this issue. In order for such efforts to be successful, parents must be empowered to freely and clearly express their attitudes towards childhood vaccination.

Current vaccine education program in Africa:

In line with the principles and areas of work outlined in the Global Vaccine Action Plan and under the advice of both the Strategic Advisory Group of Experts (SAGE) on immunization and the Task Force on Immunization (TFI), WHO/AFRO is taking steps to address vaccine preventable diseases by implementing strategies for reaching all eligible persons with effective vaccines. One of the strategies is the implementation of the African Vaccination Week (AVW), which provides a platform for Member States to speak through one collective voice to advocate for immunization as a public health priority in the Region, and to achieve high immunization coverage. The overarching objective of the initiative is to target people with limited access to regular health services, thereby working to close the gaps in immunization.

The over-arching slogan of AVW is “Vaccinated communities, Healthy communities”. Each year, a suitable theme is chosen to reflect current regional priorities and the public health realities. The first AVW was celebrated in April 2011 under the theme “Put mothers and children first – Vaccinate and stop polio now”. That year, 40 countries in the Region organized activities to celebrate the event. In subsequent years, countries have continued to conduct vaccination campaigns, catch up vaccination activities, conduct health promotion activities, and provide other child survival interventions.

To explore the shape of one AVW in particular, in 2016 they worked under the theme of “Close the immunization gap. Stay polio free!” The kick-off occurred on April 24, 2016, the same day as the kick-off of the World Immunization Week (WIW) and vaccination week in the other 5 WHO regions. The celebration of that year’s AVW also coincided with the globally synchronized switch from trivalent oral polio vaccine (tOPV) to bivalent OPV (bOPV) occurring during the period from April 17 to May 1 2016. It also followed 2 important events that had taken place during the previous 6 months: Nigeria’s removal from the list of polio-endemic countries in September 2015 (highlighting the need for countries to stay vigilant in the fight against polio) and the first ever Ministerial Conference on Immunization in Africa (MCIA) held in February 2016 in Addis Ababa, Ethiopia. The Regional launch was held in Ganta, Nimba County, Liberia on April 25 2016 during a colorful function chaired by the Deputy Minister of Health Services in the presence of high-level officials and community leaders. The event was combined with the celebration of World Malaria Day and the introduction of 2 new vaccines (rotavirus vaccine in the entire country and human papilloma vaccine (HPV) as a demonstration project) into the national immunization schedule. The Ministry of Health with support from the Ministry of Education, UNICEF, and WHO conducted a national quiz on immunization; information on immunization was sent out to schools all over the country to equip students with knowledge prior to the quizzes that were held at district, regional, and national levels. The media were engaged to disseminate messages and information especially on polio, Hepatitis B vaccination, and the HPV vaccine. Increased advocacy for mothers to attend antenatal care and to deliver from health facilities was heightened. Mothers were also being tested for HIV to prevent mother-to-child transmission of HIV.

Integration of other interventions with immunization during AVW in the African Region is common and has shown potential for improving immunization coverage, as this dedicated period is used both for catch-up campaigns and periodic intensified routine immunization. While its impact may call for further examination, it is a potential platform for integrated delivery of health interventions to people with limited access to regular health service.

Open source value assessment needs open source economics

IVI_logoThree members of the Innovation and Value Initiative (IVI) recently published a paper entitled “Open-Source Tools for Value Assessment: A Promising Approach” in the Journal of Clinical Pathways. This paper lays out, in brief, some of the ways that open-source models can contribute to the challenging environment in which value assessment operates in the US.

Unlike many nations where cost-effectiveness analysis is widely used and accepted, the US has a highly decentralized healthcare system. Even when up to date US-based models are available, they are likely not applicable to every patient population. This matters because not only does treatment response vary between populations, but so does the conception of value.

Meanwhile, healthcare decision makers must assess what evidence on value exists while simultaneously trying to assess its applicability to their patients, all without robust guidance on how to adapt the conclusions of modeling studies.

IVI has tried to change this by releasing an open-source microsimulation model for rheumatoid arthritis – a common disease whose treatment with biologics has become a significant driver of drug costs for many payers. This model is extremely flexible and speaks to the needs of healthcare decision makers by allowing for modification of treatment sequences, elements considered in the definition of value, and even whether results are formatted as a cost-effectiveness analysis or a multi-criteria decision analysis. Better still, this software is released as both a convenient web-app and as an R package with fully open code.

This is a tremendous step forward for value assessment in the US and sets a new standard for openness in modeling. Still, I can’t help but wonder how this transition from proprietary, closed models to open models will be funded. After all, IVI is in a unique position, with funding from many large pharmaceutical companies and industry organizations. If every consulting company had to organize a consortium to fund its open-source modeling initiatives, this would quickly become very burdensome.

As the “Open-Source Tools” paper points out, IVI took its inspiration for its rheumatoid arthritis model from open-source software, and we can do the same in thinking about how open-source modeling efforts could be supported. Some companies who develop open-source software support themselves by offering paid support plans for their products. A typical example here would be Canonical, which develops the Ubuntu Linux distribution. While it offers its operating system for free to anyone who wants it, it also offers paid plans that include help with deployment and maintenance.

It’s hard to know whether the scale of a typical model’s distribution would allow for this source of income, though. While Linux users number in the millions, a typical value model may have just dozens of users. Competition is likely to be important to motivate the timely development and updating of models, but the question of funding needs to be solved before more developers can take part.

The real value of an open source model depends too on the data it uses. To truly customize a model to a patient population, more granular data on patient response needs to be made available from clinical trials and disease registries. Until this happens, the conclusions of models may be based on estimated shifts in response from small samples.

The shift toward open-source modeling is an important means of responding to the challenges presented by the US healthcare market. However, many problems remain unsolved that for now still prevent more models from being developed in an open and flexible way.

Alumna interview: Meng Li

Meng Li is a recent graduate of The CHOICE Institute who defended her dissertation, “The Real Option Value of Life and Innovation,” on May 8, 2018. In addition to her dissertation research, she has published on a wide range of topics including the cost-effectiveness of liver transplantation in organic acidemias, risk-sharing agreements involving indication-specific pricing, and the acceptability of cervical cancer screening in rural Uganda. Her website is mlinternational.org.

What was your dissertation about?Genentech-636

My dissertation was about the real option value of medical technologies. The real option value of a technology refers to the value of enabling patients to live longer to be able to take advantage of future breakthroughs.  In my dissertation, I answered two closely related questions: (1) do patients consider real option value when they make their treatment decisions; and (2) how should real option value from technology advancement be incorporated in economic evaluations of medical technologies and what is the potential impact? To answer the first question, I studied metastatic melanoma patients from 2008 to 2011 and examined if they changed their treatment decisions after the announcements of the results of the breakthrough drug ipilimumab’s phase II and phase III clinical testing. The idea behind this was that, if patients considered real option value – the value of taking advantage of future innovations – they might be more likely to undergo treatments that can extend their lives. In my analysis, I found that in anticipation of ipilimumab’s arrival, metastatic melanoma patients were more likely to undergo surgical resection of metastasis, which was consistent with my hypothesis. To answer the second question, I developed methods to project likely future approvals in metastatic melanoma and potential future improvement in mortality in this patient population and incorporated them into a cost-effectiveness analysis. In my analysis, I found that the incremental QALYs increased by about 5-7% after accounting for future innovations, and the ICERs decreased by about 0-2%.

How did you arrive at that topic? When did you know that this is what you wanted to study?

I have long been interested in pricing and value assessment of medical technologies. In the short proposal phase, I brainstormed with Lou Garrison (my dissertation committee chair) and explored several topics in that area. Around that time, ISPOR also started to form a special task force to study US value assessment frameworks and Lou was the chair of the task force. As a result, a lot of our discussions back then were around the economic foundations of cost-effectiveness analysis, and benefits of a technology that are usually not accounted for in a conventional cost-effectiveness model. Real option value is one of those benefits, and it is intuitive conceptually, and relatively easy to operationalize.

What was your daily schedule like when you were working on your dissertation?

I did not have a fixed schedule when I was working on my dissertation. I usually had several research projects going on at the same time, and I tried to balance doing side projects with working on my dissertation. However, instead of spending a couple hours a day, I liked to have a few uninterrupted days when I can immerse myself in my dissertation research.

In what quarter did you submit your final short proposal and in what quarter did you graduate/defend? What were some factors that determined your dissertation timeline?

I started brainstorming ideas for dissertation in the summer of 2015, after my second year, and submitted my short proposal in March 2016, defended my dissertation proposal in February 2017, and defended my dissertation in May 2018. I would say my dissertation had a relatively slow start, as there was little existing research on the particular topic that I was studying. A lot of time was spent on thinking through the theory and developing the research plan. I probably could have finished sooner, but I decided to follow the school cycle and graduate in the Spring. I also wanted to be well prepared for my general and final exams and submit my dissertation papers to journals before I graduate.

How did you fund your dissertation?

My dissertation was not funded by any particular grant. However, I was one of the TAs for the Certificate Program in Health Economics & Outcomes Research in the Department of Pharmacy, which supported me financially during my last year in graduate school. Before that, I was the research assistant on various research projects, which provided me with financial support in the first four years of my graduate school.

What will come next for you (or has come next for you)? What have you learned about finding work after school?

I will be joining the Schaeffer Center for Health Economics & Policy at the University of Southern California as a postdoctoral scholar. My search for jobs in the past few months was mostly focused on postdoc positions. I searched job boards (Indeed and LinkedIn), career pages of professional societies (ISPOR and AcademyHealth), and websites of the groups that I am interested in working with. My advisors and colleagues also connected me with groups where there might potentially be opportunities.

Health economics in five words

There was recently a Twitter trend of people trying to describe programming in five words. The responses ranged from funny to puzzling to inspiring.

At our celebration of the end of the academic year, students, post-docs and faculty of the CHOICE Institute decided held a similar contest at our weekly seminar, and instructed attendees to “describe health economics and outcomes research (HEOR) in five words.” Here are a few of my favorite entries:

  • “How to hurt less, cheap.” (Samantha Clark)
  • “Math predicting value of medicine.” (Blythe Adamson)
  • “Examining well-being trade-offs and technology.” (Doug Barthold)
  • “Yo, treat sick people cost-effectively.” (Shuxian Chen)
  • “To each his own evaluation.” (Nobody claimed this one, unfortunately!)
  • “What is beyond opportunity cost?” (Enrique Saldarriaga)

As researchers in HEOR, the challenge of trying to explain what we do to outsiders is familiar to us all. That’s why it was really fun to try to encapsulate our field into just a few words.

Biosimilar Litigation in the United States: Redefining the Patent Dance

By Simi Grewal, MHS, PhD Student

In recent years, the U.S. pharmaceutical world has been abuzz with the emergence of biosimilars—products that are very similar, but not identical, to a reference biologic product. To date, twelve biosimilars have received FDA approval under the Biologic Price Competition and Innovation Act (BCPIA), which was passed by Congress in 2010. However, among those biosimilars that have been licensed by the FDA, only two have been marketed. While many factors influence the time lag between FDA approval and biosimilar marketing, complex patent litigation may well contribute to delays in market launch. So, let’s explore the intricate information exchange surrounding FDA biosimilar application reviews and key litigation decisions in the biosimilar landscape.

biologics
Image credit: Promega

What makes biosimilars different from generics?

First, it’s important to understand what makes biosimilars and their reference biologic products so unique. Unlike a generic for a small molecule drug, a biologic is manufactured in a living system—a complex process which is extremely challenging to exactly replicate and thus yields products that are similar to, but not exact copies of, a reference biologic. The process is also expensive. On average, R&D estimated costs for biosimilar range from $40 to $300 million and can take up to five years, whereas small molecule generics cost $2 to $5 million in R&D and can take up to three years.

What is the biosimilar “patent dance?”

With the BCPIA, Congress has made a strong effort to help improve affordability and accessibility of clinically powerful biologics. In a sense, they have sought to improve upon the Hatch-Waxman Act used for generics, by considering the unique issues that may arise as biologics reach the expiration of their 12-year patent life. Part of this intricate vetting structure is termed the “patent dance.” Indeed, the act specifies several steps to follow. 1.) After the FDA accepts an abbreviated Biologics License Application (aBLA), the BCPIA stipulates that the biosimilar maker “shall” provide its aBLA and manufacturing information to the reference biologic maker. 2) The reference biologic maker sends a list of patents that may be infringed by the biosimilar maker. 3) The biosimilar maker provides its responses. The steps continue until contentions are resolved.

Additional components of the dance are also in play. For example, the BCPIA indicates that biosimilar makers must provider 180 day notice prior to marketing their product. The guidance may have been intended to aid in resolving disputes before biosimilar market launch and assessment of damages (i.e. losses to either party from potential revenue of marketed products) complicated litigation. However, it has been criticized that if the biosimilar makers are only allowed to provide notice after FDA approval of their biosimilar, the provision essentially extends the reference biologic patent and delays market availability for a competitor. Several biosimilar makers are now providing their notice prior to FDA approval and the notice has been a component of law suits brought against biosimilar makers.

It may seem confusing that a patent dispute surrounding a single biosimilar product can become so complicated. But it’s important to consider how patents function with biologics. The patent for a new chemical entity is well-understood, but many other aspects surrounding the manufacturing process and product use can be patented—and ultimately disputed—for a biologic. The expansive landscape can lead to tens of patents surrounding a single product. AbbVie’s Humira®, for example, has recently received a great deal of attention for its protection with over 100 patents related to the product.

How have information disclosure and patent litigation for biosimilars played out so far?

Experience to date has revealed that while some biologic manufacturers follow patent dispute guidance, others seems to be setting new steps or circling around those laid out in the BCPIA altogether. In the Amgen v Sandoz case, which began in 2014 and was ultimately resolved in 2017, Sandoz refused to provide its aBLA for Zarxio®—a biosimilar to Amgen’s Neupogen®. Amgen then sued under both federal and California state law. The case ultimately landed in the Supreme Court and led to a key decision—compliance with the BCPIA’s information disclosure (i.e. the “patent dance”) cannot be enforced under both federal and state law. Instead, if a biosimilar maker does not follow the patent dance, a reference biologic maker can then sue the biosimilar maker for patent infringement. One of the more recent cases Amgen v. Adello again involves a biosimilar for Amgen’s Neupogen®. The suit by Amgen, submitted in March 2018, is essentially blind (i.e. does not specify all patent infringements by Adello) due to minimal information disclosure by Adello. In addition, Adello addresses another flex point of the BCPIA: the 180 day notice for marketing. Adello has provided this notice prior to the FDA’s approval of the biosimilar. Whether or not this marketing notice can only be provided before or after FDA approval remains a further point of contention in interpreting the Act.

What’s next in biosimilar patent litigation?

With the BCPIA in its nascent stages, we are prone to see its application become re-defined in years to come, just at Hatch-Waxman evolved in the generics market. Currently, biosimilar and reference biologic makers engage with the act’s provisions after careful consideration of how it will impact their products’ time on market and future products’ regulatory and marketing success. In the meantime, legislators are also assessing whether or not the structure of the BCPIA adequately provides a framework for achieving Congress’s goal of increasing biologic affordability and accessibility in the U.S.

Looking ahead, at least eight additional potential patent disputes are anticipated in 2018. Actions taken by private parties and stakeholders in the U.S. government will continue to define how the BCPIA is interpreted and applied in the important biologics space.